Health & Environmental Research Online (HERO)


Print Feedback Export to File
3856461 
Journal Article 
Organic anion transporting polypeptides contribute to the disposition of perfluoroalkyl acids in humans and rats 
Zhao, W; Zitzow, JD; Weaver, Y; Ehresman, DJ; Chang, SC; Butenhoff, JL; Hagenbuch, B 
2017 
Toxicological Sciences
ISSN: 1096-6080
EISSN: 1096-0929 
OXFORD UNIV PRESS 
OXFORD 
156 
84-95 
English 
Perfluoroalkyl sulfonates (PFSAs) such as perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) have very long serum elimination half-lives in humans, and preferentially distribute to serum and liver. The enterohepatic circulation of PFHxS and PFOS likely contributes to their extended elimination half-lives. We previously demonstrated that perfluorobutane sulfonate (PFBS), PFHxS, and PFOS are transported into hepatocytes both in a sodium-dependent and a sodium-independent manner. We identified Na+/taurocholate cotransporting polypeptide (NTCP) as the responsible sodium-dependent transporter. Furthermore, we demonstrated that the human apical sodium-dependent bile salt transporter (ASBT) contributes to the intestinal reabsorption of PFOS. However, so far no sodium-independent uptake transporters for PFSAs have been identified in human hepatocytes or enterocytes. In addition, perfluoroalkyl carboxylates (PFCAs) with 8 and 9 carbons were shown to preferentially distribute to the liver of rodents; however, no rat or human liver uptake transporters are known to transport these PFCAs. Therefore, we tested whether PFBS, PFHxS, PFOS, and PFCAs with 7-10 carbons are substrates of organic anion transporting polypeptides (OATPs). We used CHO and HEK293 cells to demonstrate that human OATP1B1, OATP1B3, and OATP2B1 can transport PFBS, PFHxS, PFOS, and the 2 PFCAs (C8 and C9). In addition, we show that rat OATP1A1, OATP1A5, OATP1B2, and OATP2B1 transport all 3 PFSAs. In conclusion, our results suggest that besides NTCP and ASBT, OATPs also are capable of contributing to the enterohepatic circulation and extended human serum elimination half-lives of the tested perfluoroalkyl acids. 
perfluoroalkyl sulfonates; perfluorobutane sulfonate; perfluorohexane sulfonate; perfluorooctane sulfonate; perfluoroalkyl carboxylates 
PFAS
• Additional PFAS (formerly XAgency)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
          Web of Science
          ToxNet
     Not prioritized for screening
     Perfluorooctane
     Potassium perfluorooctanoate
     Sodium perfluorooctanoate
     9-H-Perfluorononanoic acid
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               Pubmed
               WOS
     PFBS (375-73-5)
          Literature Search
               Pubmed
               WOS
     PFHxS (355-46-4)
          Literature search
               Pubmed
               WOS
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
          ToxNet
     Screened Studies
          Supplemental
     Ammonium perfluorooctanoate
     Perfluorobutanesulfonate
     Perfluorobutanesulfonic acid
     Perfluorobutanesulfonyl fluoride
     Perfluorohexanesulfonic acid
     Perfluorooctane
     Perfluorooctanesulfonic acid
     Perfluorooctanoic acid
• PFBS
          Pubmed
          WOS
          Toxicokinetic studies
               ADME
     Search
          PubMed
          WOS
     Excluded
          WOS
     Scopus: April 2021
• PFHxS
     Database searches
          Pubmed
          Toxline
          WOS
          Scopus
     Inclusion
          TiAb
     Supplemental
          Full Text
• PFNA
     Litsearch Update 2017-2018
          Toxline
     Literature Search
          Toxline
     PFNA May 2019 Update
          Toxnet
     Title and Abstract Screening
          Full Text Screening
               Excluded
                    Not PFNA
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          Pubmed
          WOS
     Screening Results
          Toxicokinetic studies
               ADME
     Literature Search Update (2013-2019)
          PubMed
          WOS
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers
• Yale PFAS Liver study